デュシェンヌ型筋ジストロフィー（DMD）治療の世界市場レポート 2025年

デュシェンヌ型筋ジストロフィー（DMD）治療市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR30.3％で473億4,000万米ドルに成長します。予測期間の成長は、デュシェンヌ型筋ジストロフィー治療への投資の増加、併用療法の採用、バイオマーカーの出現、デュシェンヌ型筋ジストロフィーのスクリーニングプログラムの増加などに起因しています。予測期間における主な動向としては、デュシェンヌ型筋ジストロフィーに対する革新的治療、標的治療の開発、新規薬剤や治療法の導入、革新的疾患修飾療法、積極的な薬剤開発などが挙げられます。

デュシェンヌ型筋ジストロフィー（DMD）治療市場の成長は、臨床試験の増加によって促進されると予測されます。臨床試験は、新しい治療、介入、薬剤の安全性、有効性、潜在的な利点を評価することを目的とした、ヒトを対象とした重要な調査です。デュシェンヌ型筋ジストロフィーの治療法に関する臨床試験の急増は、研究、技術革新、多様な治療の可能性への継続的なコミットメントを強調するものです。この動向は、患者の転帰を改善し、投資を拡大し、効果的なDMD治療法の開発と利用を加速させるものです。例えば、米国国立衛生研究所（NIH）の一部門であるClinicaltrials.govが2023年8月に報告したところによると、登録された臨床試験の数は464,218件で、2021年の399,496件から大幅に増加しています。これらの臨床試験は米国50州すべてと221カ国で実施されています。さらに、これらの試験の31％（合計142,700件）は米国内で登録されており、残りの53％（248,310件）は国際的な場所で記録されています。その結果、臨床試験数の増加がデュシェンヌ型筋ジストロフィー（DMD）治療市場拡大の原動力になると予想されます。

遺伝性疾患の有病率の上昇が、今後のデュシェンヌ型筋ジストロフィー（DMD）市場の成長を牽引すると期待されています。遺伝子疾患は、個人のDNAや遺伝物質の異常や変異によって引き起こされる疾患です。遺伝性疾患の発生が増加するにつれて、遺伝子変異や家族歴によってDMDを発症するリスクがある人口が増加する可能性があり、DMD関連の診断、治療、処置に対する需要が高まる。例えば、2022年2月、スイスに本部を置く政府間機関である世界保健機関（WHO）は、出生時の異常により、毎年生後28日以内に24万人の新生児が死亡していると報告しました。さらに、生後1カ月から5歳までの17万人の子どもが、心臓異常、神経管閉鎖障害、ダウン症などの出生時異常が原因で死亡しています。その結果、遺伝性疾患の有病率の増加がDMD市場の拡大を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場：成長率分析
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場の実績：規模と成長, 2019-2024
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小分子
• 生物学的製剤
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オフライン
• オンライン
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• ホームケア
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場、小分子のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エクソンスキッピング療法
• アンチセンスオリゴヌクレオチド
• リードスルー化合物
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場、生物製剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子治療
• 細胞療法
• タンパク質補充療法

第7章 地域別・国別分析

• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• デュシェンヌ型筋ジストロフィー（DMD）治療市場：競合情勢
• デュシェンヌ型筋ジストロフィー（DMD）治療市場：企業プロファイル
  • CVS Health Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Otsuka Holdings Co. Ltd.
• Daiichi Sankyo Co. Ltd.
• BioMarin Pharmaceutical Inc.
• Nippon Shinyaku Co. Ltd.
• CRISPR Therapeutics AG
• Sarepta Therapeutics Inc.
• PTC Therapeutics Inc.
• Halozyme Therapeutics Inc.
• FibroGen Inc.
• Exonics Therapeutics Inc.
• Italfarmaco S.p.A.
• Wave Life Sciences Ltd.
• MeiraGTx Holdings plc
• Editas Medicine Inc.
• NS Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• デュシェンヌ型筋ジストロフィー（DMD）治療市場2029：新たな機会を提供する国
• デュシェンヌ型筋ジストロフィー（DMD）治療市場2029：新たな機会を提供するセグメント
• デュシェンヌ型筋ジストロフィー（DMD）治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Duchenne muscular dystrophy (DMD) therapeutics encompass a range of medical interventions and treatments devised to address and mitigate the symptoms associated with DMD, a genetic ailment characterized by progressive muscle weakening and deterioration. The primary objective of these therapeutic strategies is to retard the advancement of the disease, enhance muscle function, and augment the overall well-being of individuals afflicted by Duchenne muscular dystrophy.

The principal categories of DMD therapeutics consist of small molecules and biologics. Small molecules are compounds with low molecular weight that can specifically interact with certain proteins or targets within the body. These can be tailored to address various facets of DMD, such as mitigating inflammation, fostering muscle regeneration, or targeting specific genetic mutations. The distribution of these therapeutics occurs through both offline and online channels, catering to applications in hospitals, clinics, and home care settings.

The duchenne muscular dystrophy (DMD) therapeutics market research report is one of a series of new reports from The Business Research Company that provides duchenne muscular dystrophy (DMD) therapeutics market statistics, including duchenne muscular dystrophy (DMD) therapeutics industry global market size, regional shares, competitors with a duchenne muscular dystrophy (DMD) therapeutics market share, detailed duchenne muscular dystrophy (DMD) therapeutics market segments, market trends and opportunities and any further data you may need to thrive in the duchenne muscular dystrophy (DMD) therapeutics industry. This duchenne muscular dystrophy (DMD) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy (DMD) therapeutics market size has grown exponentially in recent years. It will grow from $11.95 billion in 2024 to $16.45 billion in 2025 at a compound annual growth rate (CAGR) of 37.6%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, awareness about duchenne muscular dystrophy treatment, rising healthcare spending, government initiatives.

The duchenne muscular dystrophy (DMD) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $47.34 billion in 2029 at a compound annual growth rate (CAGR) of 30.3%. The growth in the forecast period can be attributed to growing investments in for duchenne muscular dystrophy treatments, adoption of combination therapies, emergence of biomarker,growing number of screening programs for duchenne muscular dystrophy. Major trends in the forecast period include innovative treatments for duchenne muscular dystrophy, development of targeted therapies, introduction of novel medications and therapies, innovative disease-modifying therapies, active drug developments.

The growth of the Duchenne muscular dystrophy (DMD) therapeutics market is anticipated to be propelled by the increasing number of clinical trials. Clinical trials represent essential research studies involving human participants aimed at assessing the safety, efficacy, and potential advantages of new medical treatments, interventions, or medications. The upsurge in clinical trials dedicated to exploring Duchenne muscular dystrophy treatments underscores the ongoing commitment to research, innovation, and a diverse range of therapeutic possibilities. This trend is poised to result in improved patient outcomes, heightened investments, and the accelerated development and accessibility of effective DMD therapies. For example, in August 2023, as reported by Clinicaltrials.gov, a branch of the National Institutes of Health (NIH), the number of registered clinical trials has increased to 464,218, marking a significant rise from 399,496 in 2021. These trials are conducted across all 50 states of the United States and in 221 countries. Additionally, 31% of these studies, totaling 142,700, are registered within the U.S., while the remaining 53% of studies (248,310) are documented in international locations. Consequently, the escalating count of clinical trials is expected to be a driving force behind the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market.

The rising prevalence of genetic disorders is expected to drive the growth of the Duchenne muscular dystrophy (DMD) market in the future. Genetic disorders are conditions caused by abnormalities or mutations in an individual's DNA or genetic material. As the occurrence of genetic disorders increases, a larger population may be at risk of developing DMD due to genetic mutations or family history, leading to greater demand for DMD-related diagnostics, treatments, and therapies. For example, in February 2022, the World Health Organization (WHO), a Switzerland-based intergovernmental body, reported that birth abnormalities cause 240,000 newborn deaths within the first 28 days of life each year. Furthermore, an additional 170,000 children aged 1 month to 5 years die due to birth abnormalities, such as heart defects, neural tube defects, and Down syndrome. As a result, the growing prevalence of genetic disorders is driving the expansion of the DMD market.

The leading companies in the field of Duchenne muscular dystrophy (DMD) therapeutics are embracing innovative technologies to enhance the effectiveness and accessibility of treatments for DMD patients while maintaining their competitive edge in the market. A case in point is Bit Bio Ltd., a UK-based synthetic biology company, which, in July 2023, introduced disease model products aimed at advancing Duchenne muscular dystrophy (DMD) treatments. These disease models, specifically the ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, consist of human skeletal myocytes engineered to carry deletions in the gene responsible for dystrophin protein production. Derived from induced pluripotent stem cells (iPSCs), Bit Bio's models offer a reliable and scalable source of human cells for research, addressing challenges associated with variability and the sourcing of primary cells. These models provide valuable insights into disease mechanisms and potential therapies, supporting the development of treatments for DMD. This technological advancement has the potential to expedite the work of researchers striving to find effective solutions for Duchenne muscular dystrophy.

In December 2022, Solid Biosciences Inc., a biotechnology firm headquartered in the United States, successfully completed the acquisition of AavantiBio, Inc. The financial details of the transaction remain undisclosed. This acquisition represents a significant move by Solid Biosciences to extend its collection of gene therapy programs, focusing on neuromuscular and cardiac diseases. The incorporation of AavantiBio, Inc. has not only broadened the company's capabilities but also brought in valuable expertise and financial resources for advancing research and development efforts and reaching potential milestones. AavantiBio, Inc., a gene therapy company based in the United States, specializes in the development of groundbreaking treatments for Duchenne muscular dystrophy and various other neuromuscular and cardiac diseases.

Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.

North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the duchenne muscular dystrophy (DMD) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The duchenne muscular dystrophy (DMD) therapeutics market includes revenues earned by entities by providing services including gene therapies, genetic testing and counseling, telehealth and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The duchenne muscular dystrophy (DMD) therapeutics market also include sales of casimersen, eteplirsen and golodirsen. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on duchenne muscular dystrophy (dmd) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for duchenne muscular dystrophy (dmd) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The duchenne muscular dystrophy (dmd) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Small Molecules; Biologics
• 2) By Distribution Channel: Offline; Online
• 3) By Application: Hospitals; Clinics; Home Care
• Subsegments:
• 1) By Small Molecules: Exon Skipping Therapies; Antisense Oligonucleotides; Read-Through Compounds
• 2) By Biologics: Gene Therapies; Cell Therapies; Protein Replacement Therapies
• Companies Mentioned: CVS Health Corporation; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; Eli Lilly and Co.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Characteristics

3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends And Strategies

4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate Analysis
• 5.4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Total Addressable Market (TAM)

6. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmentation

• 6.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecules
• Biologics
• 6.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Offline
• Online
• 6.3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care
• 6.4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exon Skipping Therapies
• Antisense Oligonucleotides
• Read-Through Compounds
• 6.5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapies
• Cell Therapies
• Protein Replacement Therapies

7. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Regional And Country Analysis

• 7.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 8.1. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 9.1. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 9.2. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 10.1. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 11.1. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 11.2. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 12.1. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 13.1. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 14.1. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 14.2. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 15.1. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 15.2. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 16.1. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 17.1. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 18.1. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 19.1. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 20.1. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 21.1. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 21.2. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 22.1. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 23.1. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 23.2. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 24.1. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 24.2. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 25.1. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 25.2. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 26.1. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 26.2. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 27.1. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 28.1. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 28.2. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 29.1. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 29.2. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Landscape
• 30.2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Company Profiles
  • 30.2.1. CVS Health Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis

31. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Other Major And Innovative Companies

• 31.1. Otsuka Holdings Co. Ltd.
• 31.2. Daiichi Sankyo Co. Ltd.
• 31.3. BioMarin Pharmaceutical Inc.
• 31.4. Nippon Shinyaku Co. Ltd.
• 31.5. CRISPR Therapeutics AG
• 31.6. Sarepta Therapeutics Inc.
• 31.7. PTC Therapeutics Inc.
• 31.8. Halozyme Therapeutics Inc.
• 31.9. FibroGen Inc.
• 31.10. Exonics Therapeutics Inc.
• 31.11. Italfarmaco S.p.A.
• 31.12. Wave Life Sciences Ltd.
• 31.13. MeiraGTx Holdings plc
• 31.14. Editas Medicine Inc.
• 31.15. NS Pharma Inc.

32. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market

34. Recent Developments In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market

35. Duchenne Muscular Dystrophy (DMD) Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer